Cost-benefit analysis of art therapy projects

Abstract

Art therapy has gained global traction as a non-pharmacological intervention that improves psychological, social, and even physiological outcomes across diverse populations. Yet the economic side of creative health practice remains under-theorised and poorly documented, leaving programme directors without evidence-informed guidelines for allocating scarce resources. This study fills that gap by fusing healthcare- economic techniques with therapeutic-outcome analytics to probe 47 art-therapy programmes operating in North America, Europe, and the Asia-Pacific region between 2020 and 2023. A convergent mixed-methods design combined forensic audits of cost ledgers, multivariate modelling of financial performance, validated clinical- outcome scales administered to 328 clients, and 116 key-informant interviews with practitioners and administrators. Programmes that instituted structured cost-benefit governance achieved an average therapeutic- adjusted return on investment (TAROI) of 2.3:1, with clinical settings peaking at 2.7:1. Adaptive, data-driven management increased resource-utilisation efficiency by 43% and boosted outcome ratings by 37% relative to static models. Optimal performance hinged on balanced resource allocation - especially maintaining personnel expenditure between 42% and 50% of total outlay - and on diversified funding streams that cushioned economic shocks. Longitudinal analysis uncovered six distinct trajectory archetypes, with continuous-improvement programmes posting a 44% rise in cost-benefit ratios over three years, while consistent-decline projects lost 30% of their initial economic value. The study distils these insights into an evidence-based management framework that reconciles fiscal prudence with therapeutic integrity, offering administrators, clinicians, and funders a pragmatic roadmap for sustaining creative-health services in volatile funding climates.